Clinical studies show that, weighed against healthy controls, serum PICP levels are higher in older individuals with diastolic cardiac dysfunction considerably, of still left ventricular hypertrophy regardless. 1. Launch Myocardial fibrosis is certainly common in a number of cardiovascular diseases, which is also a significant pathologic element in a number of cardiovascular occasions (including ramifications of center failing, arrhythmia, and unexpected cardiac loss of life) [1]. Unusual reconstruction of broken center tissue, seen as a myocardial fibrosis, is certainly a primary pathological change observed in various kinds of chronic coronary disease [2]. As a result, developing a highly effective medication treatment has turned into a concentrate of medical analysis into myocardial fibrosis. Presently, such analysis in western medication has centered on the renin-angiotensin-aldosterone program (RAAS), specifically on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARB), and aldosterone antagonists, that are known to have got a definite healing effect [3]. Nevertheless, traditional Chinese medication (TCM) gets the advantage of concentrating on many the different parts of something and providing even more integrated legislation than modern medication, which will target an individual pathological hyperlink [4]. In concentrating on myocardial fibrosis, we make an effort to treat coronary disease early by TCM, in order to enhance the cardiac microenvironment, promote regular recovery, and inhibit or change the myocardial fibrosis even. QiShenYiQi is certainly a TCM constructed AstragaliRadix Salviae miltiorrhizaeRadix NotoginsengLignum Dalbergia Odorifera[5 ofRadix, 6]. QiShenYiQi tablet (QSYQ) is accepted by China Condition Food and Medication Administration in 2003 for treatment of cardiovascular system disease, angina pectoris [7]. QSYQ allows a stable medication dosage form, which the primary effective substances are astragaloside, tanshinol, protocatechualdehyde, and ginsenosides Rb1 and Rg1 [8, 9]. Astragaloside may be the primary effective element ofRadix AstragaliRadix Salviae miltiorrhizaeRadix Notoginseng 0.05. 3. Outcomes 3.1. Aftereffect of QSYQ on Systolic BLOOD CIRCULATION PRESSURE Weighed against the sham-operated group, systolic blood circulation pressure (SBP) was more than doubled in model group ( 0.01) and showed a propensity to increase as time passes. SBP considerably low in the valsartan group weighed against the model group ( 0.01), while there is zero statistical difference in the QSYQ group ( 0.05). And SBP was low in the valsartan group than in the QYSQ group ( 0.01) (Body 1). Open up in another window Body 1 Aftereffect of QSYQ on systolic blood circulation pressure. Groupings: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are portrayed as mean SD. ** 0.01. 3.2. Aftereffect of QSYQ on HMI and LVMI Weighed against the sham-operated group, the HMI and LVMI were increased significantly in model group ( 0.01), and they increased further over time. With regard to the two treatment groups, the HMI and LVMI were significantly reduced in both the valsartan and the QSYQ group ( 0.01), and this reduction was greater over time. But the HMI and LVMI were just lower in the QSYQ group than in the valsartan group at 8 weeks ( 0.05) (Figure 2). Open in a separate window Figure 2 Effect of QSYQ on HMI and LVMI. (a) HMI of each group. (b) LVMI of each group. Groups: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are expressed as mean SD. * 0.05, ** 0.01. 3.3. Effect of QSYQ on HYP Content Compared with the sham-operated control group, the content of myocardial HYP was increased significantly in the model group at 4 weeks ( 0.01), and it increased further over time, being higher again at 8 weeks ( 0.01). With regard to the two treatment groups, the content of myocardial HYP was significantly reduced ( 0.01) in both the valsartan and the QSYQ group after 4 weeks. Although the HYP content had risen by 8 weeks, it was lower in the QSYQ group than in the valsartan group ( 0.01) (Figure 3). Open in a separate window Figure.Data are expressed as mean SD. MMP-1 and TIMP-1 expression in the myocardial rat. 1. Introduction Myocardial fibrosis is common in a variety of cardiovascular diseases, and it is also an important pathologic factor in a variety of cardiovascular events (including effects of heart failure, arrhythmia, and sudden cardiac death) [1]. Abnormal reconstruction of damaged heart tissue, characterized by myocardial fibrosis, is a core pathological change seen in many types of chronic cardiovascular disease [2]. Therefore, developing an effective drug treatment has become a focus of medical research into myocardial fibrosis. Currently, such research in western medicine has focused on the renin-angiotensin-aldosterone system (RAAS), especially on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARB), and aldosterone antagonists, which are known to have a definite therapeutic effect [3]. However, traditional Chinese medicine (TCM) has the advantage of targeting many components of a system and providing more integrated regulation than modern medicine, which tends to target a single pathological link [4]. In targeting myocardial fibrosis, we try to treat cardiovascular disease early by TCM, so as to improve the cardiac microenvironment, promote steady recovery, and even inhibit or reverse the myocardial fibrosis. QiShenYiQi is a TCM composed ofRadix AstragaliRadix Salviae miltiorrhizaeRadix NotoginsengLignum Dalbergia Odorifera[5, 6]. QiShenYiQi pill (QSYQ) is approved by China State Food and Drug Administration in 2003 for treatment of coronary heart disease, angina pectoris [7]. QSYQ enables a stable dosage form, of which the main effective ingredients are astragaloside, tanshinol, protocatechualdehyde, and ginsenosides Rg1 and Rb1 [8, 9]. Astragaloside is the main effective component ofRadix AstragaliRadix Salviae miltiorrhizaeRadix Notoginseng 0.05. 3. Results 3.1. Effect of QSYQ on Systolic Blood Pressure Compared with the sham-operated group, systolic blood pressure (SBP) was increased significantly in model group ( 0.01) and showed a tendency to increase over time. SBP significantly reduced in the valsartan group compared with the model group ( 0.01), while there was no statistical difference in the QSYQ group ( 0.05). And SBP was lower in the valsartan group than in the QYSQ group ( 0.01) (Figure 1). Open in a separate window Figure 1 Effect of QSYQ on systolic blood pressure. Groups: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are expressed as mean SD. ** 0.01. 3.2. Effect of QSYQ on HMI and LVMI Compared with the sham-operated group, the HMI and LVMI were increased significantly in model group ( 0.01), and they increased further over time. With regard to the two treatment groups, the HMI and LVMI were significantly reduced in both the valsartan and the QSYQ group ( 0.01), and this reduction was greater over time. But the HMI and LVMI were just lower in the QSYQ group than in the valsartan group at 8 weeks ( 0.05) (Figure 2). Open in a separate window Figure 2 Effect of QSYQ on HMI and LVMI. (a) HMI of each group. (b) LVMI of each group. Groups: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are expressed as mean SD. * 0.05, ** 0.01. 3.3. Effect of QSYQ on HYP Content Compared with the sham-operated control group, the content of myocardial HYP was increased significantly in the model group at 4 weeks ( 0.01), and it increased further over time, being higher again at 8 weeks ( 0.01). With regard to the two treatment groups, the content of myocardial HYP was significantly reduced ( 0.01) in both the valsartan and the QSYQ group after 4 weeks. Although the HYP content had risen by 8 weeks, it was lower in the QSYQ group than in the valsartan group ( 0.01) (Figure 3). Open in a separate window Figure 3 Effect of QSYQ on the content of HYP in rats with partial abdominal aortic coarctation. Organizations: sham-operated control (= 8), model (= 8),.** 0.01. 3.2. reconstruction of damaged heart tissue, characterized by myocardial fibrosis, is definitely a core pathological change seen in many types of chronic cardiovascular disease [2]. Consequently, developing an effective drug treatment has become a focus of medical study into myocardial fibrosis. Currently, such study in western medicine has focused on the renin-angiotensin-aldosterone system (RAAS), especially on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARB), and aldosterone antagonists, which are known to possess a definite restorative effect [3]. However, traditional Chinese medicine (TCM) has the advantage of focusing on many components of a system and providing more integrated rules than modern medicine, which tends to target a single pathological link [4]. In focusing on myocardial fibrosis, we try to treat cardiovascular disease early by TCM, so as to improve the cardiac microenvironment, promote stable recovery, and even inhibit or reverse the myocardial fibrosis. QiShenYiQi is definitely a TCM made up ofRadix AstragaliRadix Salviae miltiorrhizaeRadix NotoginsengLignum Dalbergia Odorifera[5, 6]. QiShenYiQi pill (QSYQ) is definitely authorized by China State Food and Drug Administration in 2003 for treatment of coronary heart disease, angina pectoris [7]. QSYQ enables a stable dose form, of which the main effective elements are astragaloside, tanshinol, protocatechualdehyde, and ginsenosides Rg1 and Rb1 [8, 9]. Astragaloside is the main effective component ofRadix AstragaliRadix Salviae miltiorrhizaeRadix Notoginseng 0.05. 3. Results 3.1. Effect of QSYQ on Systolic Blood Pressure Compared with the sham-operated group, systolic blood pressure (SBP) was increased significantly in model group ( 0.01) and showed a inclination to increase over time. SBP significantly reduced in the valsartan group compared with the model group ( 0.01), while there was no statistical difference in the QSYQ group ( 0.05). And SBP was reduced the valsartan group than in the QYSQ group ( 0.01) (Number 1). Open in a separate window Number 1 Effect of QSYQ on systolic blood pressure. Organizations: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are indicated as mean SD. ** 0.01. 3.2. Effect of QSYQ on HMI and LVMI Compared with the sham-operated group, the HMI and LVMI were increased significantly in model group ( 0.01), and they increased further over time. With regard to the two treatment organizations, the HMI and LVMI were significantly reduced in both the valsartan and the QSYQ group ( 0.01), and this reduction was higher over time. But the HMI and LVMI were just reduced the QSYQ group than in the valsartan group at 8 weeks ( 0.05) (Figure 2). Open ICOS in a separate window Number 2 Effect of QSYQ on HMI and LVMI. (a) HMI of each group. (b) LVMI of each group. Organizations: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are indicated as mean SD. * 0.05, ** 0.01. 3.3. Effect of QSYQ on HYP Content Compared with the sham-operated control group, the content of myocardial HYP was increased significantly in the model group at 4 weeks ( 0.01), and it increased further over time, being higher again at 8 weeks ( 0.01). With regard to the two treatment groups, the content of myocardial HYP was significantly reduced ( 0.01) in both the valsartan and the QSYQ group after 4 weeks. Even though HYP content experienced risen by 8 weeks, it was reduced the QSYQ group than in the valsartan group ( 0.01) (Number 3). Open in a separate window Number 3 Effect of QSYQ on the content of HYP in rats with partial abdominal aortic coarctation. Organizations: sham-operated control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are indicated as mean SD. ** 0.01. 3.4. Effect of QSYQ within the Synthesis and Degradation of Myocardial Collagen Compared with the sham-operated control group, the concentration of serum PICP and PIIINP and the percentage of PICP/PIIINP increased significantly ( 0.01) in the model group and showed a tendency to increase over time. Valsartan significantly decreased the concentration of serum PICP and PIIIN ( 0.01 and 0.05, resp.) and significantly decreased the percentage of PICP/PIIINP at 8 weeks ( 0.05). A similar result was seen with the QSYQ group, except that its effect was significantly greater than that of valsartan at 8 weeks ( 0.01, 0.05) (Figure 4). Open in a separate window Number 4 Effect of QSYQ on synthesis and.Therefore, the content of myocardial HYP can be an indirect reflection of the level of myocardial collagen, and the content of myocardial HYP in fibrotic lesions is definitely positively correlated with the degree of fibrosis [17]. cardiovascular diseases, and it is also an important pathologic factor in a variety of cardiovascular events (including effects of heart failure, arrhythmia, and sudden cardiac death) [1]. Irregular reconstruction of damaged heart tissue, characterized by myocardial fibrosis, is definitely a core pathological change seen in many types of chronic cardiovascular disease [2]. Consequently, developing an effective drug treatment has become a focus of medical study into myocardial fibrosis. Currently, such study in western medicine has focused on the renin-angiotensin-aldosterone system (RAAS), especially on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARB), and aldosterone antagonists, which are known to possess a definite restorative effect [3]. However, traditional Chinese medicine (TCM) has the advantage of focusing on many components of a system and providing more integrated rules than modern medicine, which tends to target a single pathological link [4]. In focusing on myocardial fibrosis, we try to treat cardiovascular disease early by TCM, so as to improve the cardiac microenvironment, promote constant recovery, and even inhibit or reverse the myocardial fibrosis. QiShenYiQi is definitely a TCM made up ofRadix AstragaliRadix Salviae miltiorrhizaeRadix NotoginsengLignum Dalbergia Odorifera[5, 6]. QiShenYiQi pill (QSYQ) is definitely authorized by China State Food and Drug Administration in 2003 for treatment of coronary heart disease, angina pectoris [7]. QSYQ enables a stable dose form, of which the main effective elements are astragaloside, tanshinol, protocatechualdehyde, and ginsenosides Rg1 and Rb1 [8, 9]. Astragaloside is the main effective component ofRadix AstragaliRadix Salviae miltiorrhizaeRadix Notoginseng 0.05. 3. Results 3.1. Effect of QSYQ on Systolic Blood Pressure Compared with the sham-operated group, systolic blood pressure (SBP) was increased significantly in model group ( 0.01) and showed a inclination to increase over time. SBP significantly reduced in the valsartan group compared with the model group ( 0.01), while there was no statistical difference in the QSYQ group ( 0.05). And SBP was reduced the valsartan group than in the QYSQ group ( 0.01) (Number 1). Open in a separate window Number 1 Effect of QSYQ on systolic blood pressure. Organizations: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are indicated as mean SD. ** 0.01. 3.2. Effect of QSYQ on HMI and LVMI Compared with the sham-operated group, the HMI and LVMI were increased significantly in model group ( 0.01), and they increased further over time. With regard to the two treatment organizations, the HMI and LVMI were significantly reduced in both the valsartan and the QSYQ group ( 0.01), and this reduction was higher over time. But the HMI and LVMI were just reduced the QSYQ group than in the valsartan group at 8 weeks ( 0.05) (Figure 2). Open in a separate window Number 2 Effect of QSYQ on HMI and LVMI. (a) HMI of each group. (b) LVMI of each group. Organizations: control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are indicated as mean SD. * 0.05, ** 0.01. 3.3. Effect of QSYQ on HYP Content Compared with the sham-operated control group, the content of myocardial HYP was increased significantly in the model group at 4 weeks ( 0.01), and it increased further over time, being higher again at 8 weeks ( 0.01). With regard to the two treatment groups, the content of myocardial HYP was significantly reduced ( 0.01) in both the valsartan and the QSYQ group after 4 weeks. Even though HYP content experienced risen by 8 weeks, it was reduced the QSYQ group than in the valsartan L-Glutamic acid monosodium salt group ( 0.01) (Number 3). Open in a separate window L-Glutamic acid monosodium salt Number 3 Effect of QSYQ on the content of HYP in rats with partial abdominal aortic coarctation. Organizations: sham-operated control (= 8), model (= 8), valsartan (= 8), and QSYQ (= 8). Data are indicated as mean SD. ** 0.01. 3.4. Effect of QSYQ within the Synthesis and Degradation of Myocardial Collagen Compared with the sham-operated control group, the concentration of serum PICP and PIIINP and the percentage of PICP/PIIINP increased significantly ( 0.01) in the model group and showed a tendency to increase over time. Valsartan significantly decreased the L-Glutamic acid monosodium salt concentration of serum PICP and PIIIN ( 0.01 and 0.05, resp.) and significantly decreased the percentage of PICP/PIIINP at 8 weeks ( 0.05). A similar result was seen with the QSYQ group, except that its effect was significantly.